Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

2014116 citationsJournal Articlehybrid Open Access

Authors

In subjects with T2DM and stage 3 CKD, canagliflozin reduced HbA1c, body weight, and blood pressure, and was generally well tolerated.

Good health and well-being

Published in: American Journal of Nephrology

Volume 40, Issue 1, pp. 64-74

Field-Weighted Citation Impact: 12.01